{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:15:55Z","timestamp":1792512955022,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2017SGR-01508"],"award-info":[{"award-number":["2017SGR-01508"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017521","name":"Esteve Pharmaceuticals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005051","name":"MPS Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011104","name":"Universitat Aut\u00f2noma de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003741","name":"Instituci\u00f3 Catalana de Recerca i Estudis Avan\u00e7ats","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Generalitat de Catalunya Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.omtm.2021.09.017","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T21:26:44Z","timestamp":1633469204000},"page":"370-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal"],"prefix":"10.1016","volume":"23","author":[{"given":"Sara","family":"Marc\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Haurigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Ja\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-4276","authenticated-orcid":false,"given":"Albert","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Molas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bertolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Pumarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Andaluz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Espada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"A\u00f1or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7705-5515","authenticated-orcid":false,"given":"Fatima","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2021.09.017_bib1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/hum.2016.087","article-title":"Adeno-Associated Virus-Based Gene Therapy for CNS Diseases","volume":"27","author":"Hocquemiller","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib2","series-title":"Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/978-1-4939-3271-9_30","article-title":"Gene therapy for the treatment of neurological disorders: metabolic disorders","author":"Gessler","year":"2016"},{"key":"10.1016\/j.omtm.2021.09.017_bib3","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1089\/hum.2019.190","article-title":"Gene-based approaches to inherited neurometabolic diseases","volume":"30","author":"Poletti","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2352-4642(17)30087-1","article-title":"Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS","volume":"2","author":"Giugliani","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.omtm.2021.09.017_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.omtm.2021.09.017_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.22092","article-title":"Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations","volume":"68","author":"Valstar","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2021.09.017_bib8","doi-asserted-by":"crossref","first-page":"e1255","DOI":"10.1542\/peds.2007-0282","article-title":"Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)","volume":"120","author":"Meyer","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.omtm.2021.09.017_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ymgme.2016.08.002","article-title":"A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design","volume":"119","author":"Truxal","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.017_bib10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpeds.2015.11.079","article-title":"A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA","volume":"170","author":"Shapiro","year":"2016","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtm.2021.09.017_bib11","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/ajmg.a.40351","article-title":"Mucopolysaccharidosis III in Taiwan: Natural history, clinical and molecular characteristics of 28 patients diagnosed during a 21-year period","volume":"176","author":"Lin","year":"2018","journal-title":"Am. J. Med. Genet. A."},{"key":"10.1016\/j.omtm.2021.09.017_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ymgme.2021.04.006","article-title":"Longitudinal MRI brain volume changes over one year in children with mucopolysaccharidosis types IIIA and IIIB","volume":"133","author":"Abreu","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.017_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/jcm9020344","article-title":"Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease","volume":"9","author":"Heon-Roberts","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omtm.2021.09.017_bib14","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3171\/FOC\/2008\/24\/3-4\/E11","article-title":"Central nervous system therapy for lysosomal storage disorders","volume":"24","author":"Enns","year":"2008","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.omtm.2021.09.017_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2021.09.017_bib16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2021.09.017_bib18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/15548627.2018.1474313","article-title":"Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency","volume":"14","author":"Lotfi","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.omtm.2021.09.017_bib19","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/hum.2012.029","article-title":"Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer","volume":"23","author":"Ruzo","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib20","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omtm.2021.09.017_bib23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2021.09.017_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3171\/2010.4.PEDS09507","article-title":"Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations","volume":"6","author":"Souweidane","year":"2010","journal-title":"J.\u00a0Neurosurg. Pediatr."},{"key":"10.1016\/j.omtm.2021.09.017_bib26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/hum.2012.052","article-title":"Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain","volume":"23","author":"Salegio","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib27","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/mt.2013.86","article-title":"Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy","volume":"21","author":"Bradbury","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib28","first-page":"48","article-title":"Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes","volume":"6","author":"Gilkes","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2021.09.017_bib29","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1089\/hum.2018.189","article-title":"An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA","volume":"30","author":"Gray","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/hum.2015.170","article-title":"A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome","volume":"27","author":"Winner","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib31","doi-asserted-by":"crossref","first-page":"165ra163","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2021.09.017_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/hmg\/ddp475","article-title":"Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate","volume":"19","author":"Colle","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2021.09.017_bib33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/hum.2008.155","article-title":"Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution","volume":"20","author":"Ciron","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib34","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1172\/JCI66778","article-title":"Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy","volume":"123","author":"Haurigot","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2021.09.017_bib35","doi-asserted-by":"crossref","first-page":"e86696","DOI":"10.1172\/jci.insight.86696","article-title":"CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Motas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2021.09.017_bib36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib37","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/mt.2015.189","article-title":"Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII","volume":"24","author":"Gurda","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib39","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/hmg\/ddu727","article-title":"Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy","volume":"24","author":"Ribera","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2021.09.017_bib40","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I","volume":"22","author":"Hinderer","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/gt.2016.6","article-title":"Intracerebroventricular delivery of self-complementary adeno-associated virus serotype 9 to the adult rat brain","volume":"23","author":"Donsante","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/mt.2015.212","article-title":"A Comprehensive Map of CNS Transduction by Eight Recombinant Adeno-associated Virus Serotypes Upon Cerebrospinal Fluid Administration in Pigs","volume":"24","author":"Sorrentino","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2010.265","article-title":"Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib44","doi-asserted-by":"crossref","first-page":"14051","DOI":"10.1038\/mtm.2014.51","article-title":"Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna","volume":"1","author":"Hinderer","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2021.09.017_bib45","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/hmg\/ddx058","article-title":"Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID","volume":"26","author":"Roca","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2021.09.017_bib46","series-title":"Neurosurgical Operative Atlas","first-page":"171","article-title":"Technique of ventriculostomy","author":"Piatt","year":"1991"},{"key":"10.1016\/j.omtm.2021.09.017_bib47","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1089\/hum.2019.012","article-title":"Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys","volume":"30","author":"Hordeaux","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib48","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtm.2018.06.004","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2021.09.017_bib51","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/hum.2020.116","article-title":"Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates","volume":"31","author":"Ballon","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2021.09.017_bib53","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/hum.2019.217","article-title":"In\u00a0Vivo Gene Therapy for Mucopolysaccharidosis Type III (Sanfilippo Syndrome): A New Treatment Horizon","volume":"30","author":"Marc\u00f3","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neuroimage.2005.07.008","article-title":"Neuroanatomical differences between mouse strains as shown by high-resolution 3D MRI","volume":"29","author":"Chen","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.omtm.2021.09.017_bib55","first-page":"19","article-title":"Longitudinal Brain Size Measurements in App\/Ps1 Transgenic Mice","volume":"4","author":"Vincent","year":"2010","journal-title":"Magn. Reson. Insights"},{"key":"10.1016\/j.omtm.2021.09.017_bib56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0006-8993(73)90188-1","article-title":"Genetic and phenotypic variation in weight of brain and spinal cord between inbred strains of mice","volume":"64","author":"Roderick","year":"1973","journal-title":"Brain Res."},{"key":"10.1016\/j.omtm.2021.09.017_bib57","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.neuroscience.2005.07.014","article-title":"A three-dimensional digital atlas database of the adult C57BL\/6J mouse brain by magnetic resonance microscopy","volume":"135","author":"Ma","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.omtm.2021.09.017_bib58","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/87565641003696833","article-title":"Associations between IQ, total and regional brain volumes, and demography in a large normative sample of healthy children and adolescents","volume":"35","author":"Lange","year":"2010","journal-title":"Dev. Neuropsychol."},{"key":"10.1016\/j.omtm.2021.09.017_bib59","doi-asserted-by":"crossref","first-page":"313ra180","DOI":"10.1126\/scitranslmed.aac6191","article-title":"AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease","volume":"7","author":"Katz","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2021.09.017_bib60","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/jgm.1480","article-title":"Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery","volume":"12","author":"Fu","year":"2010","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2021.09.017_bib61","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ymgme.2009.07.013","article-title":"Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study","volume":"98","author":"Hemsley","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.017_bib62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ymgme.2015.03.002","article-title":"Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice","volume":"115","author":"Beard","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.017_bib63","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1182\/blood-2009-12-261156","article-title":"Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B","volume":"115","author":"Arruda","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2021.09.017_bib64","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib65","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/mt.2015.99","article-title":"Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates","volume":"23","author":"Hinderer","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymgme.2016.06.006","article-title":"Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model","volume":"119","author":"Hinderer","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.017_bib67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2021.09.017_bib68","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the Center of the Cell: Tracing the Path of AAV Transduction","volume":"27","author":"Dhungel","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtm.2021.09.017_bib69","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2012.05.005","article-title":"Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II","volume":"107","author":"Higuchi","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.017_bib70","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","article-title":"A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA","volume":"118","author":"Jones","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.017_bib71","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2018.10.006","article-title":"Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial","volume":"126","author":"Wijburg","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.017_bib72","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.ymgme.2018.12.083","article-title":"ICV-administered tralesinidase alfa (BMN 250 NAGLU-IGF2) is well-tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB)","volume":"126","author":"Cleary","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.017_bib73","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.05.009","article-title":"Intrathecal delivery of protein therapeutics to the brain: a critical reassessment","volume":"144","author":"Calias","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib74","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1\/2 Trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib75","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajmg.a.38073","article-title":"Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I","volume":"173","author":"Nestrasil","year":"2017","journal-title":"Am. J. Med. Genet. A."},{"key":"10.1016\/j.omtm.2021.09.017_bib76","doi-asserted-by":"crossref","first-page":"559804","DOI":"10.3389\/fmolb.2020.559804","article-title":"CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges","volume":"7","author":"Edelmann","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omtm.2021.09.017_bib77","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1073\/pnas.0711637105","article-title":"Revisiting neural stem cell identity","volume":"105","author":"Nakafuku","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.09.017_bib78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0092-8674(00)80956-3","article-title":"Identification of a neural stem cell in the adult mammalian central nervous system","volume":"96","author":"Johansson","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2021.09.017_bib79","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1073\/pnas.0710000105","article-title":"CD133+ neural stem cells in the ependyma of mammalian postnatal forebrain","volume":"105","author":"Coskun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.09.017_bib80","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1267\/ahc.37.81","article-title":"Proliferation of Leptomeningeal Cells in Delayed Neuronal Death in Gerbils","volume":"37","author":"Kataoka","year":"2004","journal-title":"Acta Histochem. Cytochem."},{"key":"10.1016\/j.omtm.2021.09.017_bib81","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tvjl.2005.07.021","article-title":"The function, composition and analysis of cerebrospinal fluid in companion animals: part I - function and composition","volume":"172","author":"Di Terlizzi","year":"2006","journal-title":"Vet. J."},{"key":"10.1016\/j.omtm.2021.09.017_bib82","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anorl.2011.03.002","article-title":"Anatomy and physiology of cerebrospinal fluid","volume":"128","author":"Sakka","year":"2011","journal-title":"Eur. Ann. Otorhinolaryngol. Head Neck Dis."},{"key":"10.1016\/j.omtm.2021.09.017_bib83","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2005-08-3229","article-title":"Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice","volume":"107","author":"Scallan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2021.09.017_bib84","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2021.09.017_bib85","doi-asserted-by":"crossref","first-page":"eaba9188","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2021.09.017_bib86","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2021.09.017_bib87","doi-asserted-by":"crossref","first-page":"e2020069","DOI":"10.4084\/mjhid.2020.069","article-title":"Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century","volume":"12","author":"Arruda","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.omtm.2021.09.017_bib88","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1172\/JCI133953","article-title":"Krabbe disease successfully treated via monotherapy of intrathecal gene therapy","volume":"130","author":"Bradbury","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2021.09.017_bib89","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/00480169.2000.36181","article-title":"Mucopolysaccharidosis IIIA (Sanfilippo syndrome) in a New Zealand Huntaway dog with ataxia","volume":"48","author":"Jolly","year":"2000","journal-title":"N.\u00a0Z. Vet. J."},{"key":"10.1016\/j.omtm.2021.09.017_bib90","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1203\/00006450-199807000-00012","article-title":"Sulfamidase deficiency in a family of Dachshunds: a canine model of mucopolysaccharidosis IIIA (Sanfilippo A)","volume":"44","author":"Fischer","year":"1998","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.omtm.2021.09.017_bib91","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/vr.148.18.564","article-title":"Histological diagnosis of mucopolysaccharidosis IIIA in a wire-haired dachshund","volume":"148","author":"Jolly","year":"2001","journal-title":"Vet. Rec."},{"key":"10.1016\/j.omtm.2021.09.017_bib92","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/geno.2002.6699","article-title":"Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs","volume":"79","author":"Yogalingam","year":"2002","journal-title":"Genomics"},{"key":"10.1016\/j.omtm.2021.09.017_bib93","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.nbd.2011.04.014","article-title":"Enzyme replacement reduces neuropathology in MPS IIIA dogs","volume":"43","author":"Crawley","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtm.2021.09.017_bib94","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/mthe.2001.0442","article-title":"Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation","volume":"4","author":"Herzog","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib95","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gt.2009.157","article-title":"High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency","volume":"17","author":"Ayuso","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.017_bib96","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1242\/dmm.025171","article-title":"Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC","volume":"9","author":"Marc\u00f3","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtm.2021.09.017_bib97","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121001558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121001558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:53:47Z","timestamp":1778867627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050121001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":97,"alternative-id":["S2329050121001558"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2021.09.017","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2021.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}